The BrainOnly™ platform is Montara's core technology designed to facilitate brain-specific drug activity. It enables the development of therapies that selectively target neurological conditions while avoiding the toxicities typically associated with systemic treatments.

• ·Supports two-drug combination therapies with a brain-penetrant drug and a non-brain penetrant peripheral blocker.
• ·Enhances the safety and efficacy profile of existing neurological drugs.
• ·Enables the targeting of previously considered 'undruggable' pathways related to brain diseases.